ODTX Overview

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its advanced programs include OD-001, an oral small-molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, and OD-002, an oral small-molecule inhibitor of solute carrier family 15 member 4, or SLC15A4. These programs have the potential to yield treatments for inflammatory and autoimmune diseases. In addition to its advanced programs, it has a portfolio of preclinical programs that include a regulatory T cell, or Treg, -specific tumor necrosis factor receptor 2, or TNFR2, agonist, a bispecific antagonist of thymic stromal lymphopoietin, or TSLP, and interleukin-33, or IL-33, and an interleukin-1 receptor-associated kinase 4, or IRAK4, scaffolding inhibitor. It also has an interferon regulatory factor 5, or IRF5, inhibitor in preclinical development.

Wall Street analysts forecast ODTX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ODTX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Odyssey Therapeutics Inc revenue for the last quarter amounts to 1.75M USD, increased 511.50

Odyssey Therapeutics Inc. EPS for the last quarter amounts to -0.76 USD, increased 24.59

Odyssey Therapeutics Inc (ODTX) has 100 emplpoyees as of June 02 2026.

Today ODTX has the market capitalization of 801.44M USD.